Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.55 |
| ▸ | BCHE | P06276 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006005 | 0.88 | GAA (0.58) | GAAATMCHRM2CHRM1CHRM3 | |
| SCHEMBL5009379 | 0.88 | GAA (0.64) | GAAATMCHRM2CHRM1CHRM3 | |
| SCHEMBL5003333 | 0.88 | GAA (0.58) | GAAATMCHRM2CHRM1CHRM3 | |
| SCHEMBL5011132 | 0.86 | GAA (0.58) | GAAATMCHRM2CHRM1CHRM3 | |
| SCHEMBL7066702 | 0.82 | CHRM3 (0.68) | GAAATMCHRM2CHRM1CHRM3 | |
| Bromide SCHEMBL9050852 | 0.81 | CHRM3 (0.67) | GAAATMCHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL5003293 | 0.81 | CHRM3 (0.67) | GAAATMCHRM2CHRM1CHRM3 | |
| SCHEMBL4084020 | 0.81 | GAA (0.70) | GAAATMCHRM2CHRM1CHRM3 | |
| SCHEMBL5007294 | 0.81 | CHRM3 (0.37) | GAAATMCHRM2CHRM1CHRM3 | |
| SCHEMBL5007163 | 0.79 | GAA (0.61) | GAAATMCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461336-B1 | 1-ALKYL-1-AZONIABICYCLO (2.2.2) OCTANE CARBAMATE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | CHIESI FARMA SPA (IT) | 2013-05-22 | — | — | EP | disclosed |
| US-7452904-B2 | 1-alkyl-1-azoniabicyclo' 2.2.2 octane carbamate derivatives and their use as muscarinic receptor antagonists | CHIESI FARMACEUTICI S.P.A. (IT) | 2008-11-18 | — | — | US | disclosed |
| US-20050043349-A1 | 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists | LABORATORIOS S.A.L.V.A.T. (ES) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043349-A1 | 1-Alkyl-1-azoniabicyclo' 2.2.!octane carbamate derivatives and their use as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | GAA 4508/4885ATM 2028/4885CHRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.